Invitae Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 1,235

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $241M

  • Investors
  • 2

Invitae General Information

Description

Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.

Contact Information

Website
www.invitae.com
Formerly Known As
Locus Development, Locus Development Inc
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 1400 16th Street
  • San Francisco, CA 94103
  • United States
+1 (800)
Primary Industry
Clinics/Outpatient Services
Parent Company
Labcorp Holdings
Corporate Office
  • 1400 16th Street
  • San Francisco, CA 94103
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Invitae Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 05-Aug-2024 $241M Completed Generating Revenue
14. Bankruptcy: Admin/Reorg 13-Feb-2024 Completed Bankruptcy: Admin/Reorg
13. PIPE 05-Oct-2020 Completed Generating Revenue
12. PIPE 07-Nov-2018 Completed Generating Revenue
11. Secondary Transaction - Open Market 05-Apr-2018 Completed Generating Revenue
10. PIPE 31-Aug-2017 Completed Generating Revenue
9. Secondary Transaction - Open Market 06-Apr-2017 Completed Generating Revenue
8. IPO 12-Feb-2015 Completed Generating Revenue
7. Later Stage VC (Series F) 13-Oct-2014 $120M $206M Completed Generating Revenue
6. Later Stage VC (Series E) 10-Dec-2013 $40M $85.5M Completed Generating Revenue
To view Invitae’s complete valuation and funding history, request access »

Invitae Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series F
Series E
Series D
Series C
Series B 4,181,818 $0.000100 $0.04 $0.55 $0.55 1x $0.55 2.61%
Series A 11,693,179 $0.000100 $0.04 $0.44 $0.44 1x $0.44 7.3%
To view Invitae’s complete cap table history, request access »

Invitae Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include
Clinics/Outpatient Services
San Francisco, CA
1,235 As of 2024

Salt Lake City, UT
 

Palo Alto, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Invitae Competitors (11)

One of Invitae’s 11 competitors is Myriad Genetics, a Corporation company based in Salt Lake City, UT.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Myriad Genetics Corporation Salt Lake City, UT
Guardant Health Formerly VC-backed Palo Alto, CA
Natera Formerly VC-backed Austin, TX
Fulgent Genetics Formerly VC-backed El Monte, CA
Blueprint Genetics Formerly VC-backed Espoo, Finland
You’re viewing 5 of 11 competitors. Get the full list »

Invitae Patents

  • 104

    Total Documents Applications and Grants

  • Total Patents Families

  • 43

    Granted

  • 5

    Pending

  • Expiring in next 12 mo

Invitae Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024254269-A2 Genetic prevalence estimator using panel distance Inactive 07-Jun-2023
WO-2024254269-A3 Genetic prevalence estimator using panel distance Inactive 07-Jun-2023
WO-2024254269-A8 Genetic prevalence estimator using panel distance Inactive 07-Jun-2023
WO-2024129844-A1 Techniques for designing patient-specific panels and methods of use thereof for detecting minimal residual disease Inactive 14-Dec-2022
WO-2024097261-A1 Population frequency modeling for quantitative variant pathogenicity estimation Inactive 01-Nov-2022 G16B40/00
To view Invitae’s complete patent history, request access »

Invitae Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Invitae Former Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
Baker Brothers Investments Hedge Fund Minority
BlackRock Asset Manager Minority
Casdin Capital Venture Capital Minority
Casdin Capital Partners Corporation Minority
Decheng Capital Venture Capital Minority
You’re viewing 5 of 21 investors. Get the full list »

Invitae Acquisitions (16)

Invitae’s most recent deal was a Merger/Acquisition with Stratify Genomics for . The deal was made on 23-Dec-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Stratify Genomics 23-Dec-2021 Merger/Acquisition Diagnostic Equipment
Citizen Health 14-Sep-2021 Merger/Acquisition Medical Records Systems
Genosity (Iselin) 05-Apr-2021 Merger/Acquisition Biotechnology
MedNeon 24-Feb-2021 Merger/Acquisition Decision/Risk Analysis
One Codex 01-Feb-2021 Merger/Acquisition Other Healthcare Technology Systems
You’re viewing 5 of 16 acquisitions. Get the full list »

Ready to get started?

Request a free trial

Invitae ESG

Risk Overview

Risk Rating

Updated October, 31, 2024

27.96 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,744

Rank

Percentile

Pharmaceuticals

Industry

of 853

Rank

Percentile

Biotechnology

Subindustry

of 369

Rank

Percentile

To view Invitae’s complete esg history, request access »

Invitae Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
One Codex Wilmington, DE 2014

Invitae FAQs

  • When was Invitae founded?

    Invitae was founded in 2010.

  • Where is Invitae headquartered?

    Invitae is headquartered in San Francisco, CA.

  • What is the size of Invitae?

    Invitae has 1,235 total employees.

  • What industry is Invitae in?

    Invitae’s primary industry is Clinics/Outpatient Services.

  • Is Invitae a private or public company?

    Invitae is a Private company.

  • What is the current valuation of Invitae?

    The current valuation of Invitae is .

  • What is Invitae’s current revenue?

    The current revenue for Invitae is .

  • How much funding has Invitae raised over time?

    Invitae has raised $653M.

  • Who are Invitae’s investors?

    Baker Brothers Investments, BlackRock, Casdin Capital, Casdin Capital Partners, and Decheng Capital are 5 of 21 investors who have invested in Invitae.

  • Who are Invitae’s competitors?

    Myriad Genetics, Guardant Health, Natera, Fulgent Genetics, and Blueprint Genetics are some of the 11 competitors of Invitae.

  • When was Invitae acquired?

    Invitae was acquired on 05-Aug-2024.

  • Who acquired Invitae?

    Invitae was acquired by Labcorp Holdings.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process